immatics enters Collaboration with the National Cancer Institute (NCI) to Advance the Development of IMA950 for Glioblastoma
Multi-target therapeutic cancer vaccine IMA950 to enter second clinical phase I study for glioblastoma, the most aggressive form of brain cancer
Under the terms of the agreement, CCR will sponsor and conduct a phase I trial of IMA950 which will be carried out at the National Institute of Health's (NIH's) Facility in Bethesda, Maryland, U.S. The phase I trial will evaluate IMA950 in stable or recurrencefree glioblastoma patients following standard radiochemotherapy with temozolomide.
The principal investigator of the study is Dr. Howard Fine, Chief of the Neuro-Oncology Branch at the National Cancer Institute. immatics will collaborate with CCR and will also be responsible for drug supply for the study as well as undertaking immunomonitoring of the treated patients.
This collaboration follows an agreement immatics signed with Cancer Research UK in February for the clinical development of IMA950 in glioblastoma. The Cancer Research UK sponsored study will treat newly diagnosed patients with IMA950 in combination with radiochemotherapy while this study at the NCI will treat patients after successful radiochemotherapy with standalone IMA950. The different protocols for these two studies should mean that they provide complementary data reflecting the different clinical situations experienced by glioblastoma patients.
Paul Higham, CEO of immatics said: "We are delighted to be collaborating with such a prestigious organization as the National Cancer Institute to help us to develop our third therapeutic vaccine, IMA950. Our ability to secure two such highly regarded collaborators to advance IMA950 into the clinic demonstrates the significant interest in immatics' novel therapeutic vaccines and the need for a much improved treatment option for glioblastoma. We very much look forward to working with the NCI to further develop IMA950 and to evaluate how it may be of benefit in this devastating disease."
IMA950 is a therapeutic cancer vaccine generated through immatics' proprietary XPRESIDENT(TM) technology. It consists of 11 tumorassociated peptides (TUMAPs) which the immatics platform selected on the basis of their natural presentation by tumor tissue, overexpression in tumor vs. healthy tissue, immunogenicity and their relevance to tumor function. This unique approach to rationally designed therapeutic vaccines which are a combination of multiple, highly relevant tumor peptides is at the core of all immatics' clinical programs.
The US National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI is the Federal Government's principal agency for cancer research and training. The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.
About immatics biotechnologies GmbH
immatics biotechnologies is a clinicalstage biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer. immatics' lead product, IMA901 has completed a phase II trial in renal cell carcinoma. immatics' pipeline also includes IMA910, in phase II for colorectal cancer, and IMA950 which is being developed for glioma.
immatics' technology platform rapidly generates defined therapeutic cancer vaccines which are based on multiple tumorassociated peptides (TUMAPs) with the ability to specifically stimulate the immune system against cancer cells. These vaccines - comprising multiple peptides confirmed to be naturally presented by real tumor tissue
- offer the prospect of greater effectiveness than existing cancer vaccine approaches.
immatics' products are 'drug like' with stable, offtheshelf formulations and robust easily scalable manufacturing.
immatics is based in Tuebingen and Munich, Germany, and has raised more than €54 million in private equity in two financing rounds.